Despite being highly preventable, ischemia is a contributory factor in over 10 million deaths each year (excluding ischemic stroke and ischemic heart disease ). Ischemia is a condition where the cells do not get enough oxygen to survive because of inadequate blood supply, and can occur as a result of many conditions; restricted blood flow due to a blockage, a thrombus, embolus or external pressure on a blood vessel causing obstruction to blood supply in the organ (myocardial infarction, stroke and many other), trauma (e.g. haemorrhagic shock; compartment syndrome) and infection (e.g. sepsis). Complications may also occur after surgery (e.g. reconstruction/replantation surgery where clots may form in the anastomosed vessels and cause flap necrosis (tissue death)).
Ischemia is often a very curable condition if detected quickly. Unfortunately, consistent visual symptoms are rarely present in this vital early period and ischemia is often left to progress undetected. Insufficient diagnostic technology is available to assist healthcare providers in the timely diagnosis and continuous monitoring of patients where oxygen limitation or cellular dysfunction is concerned.
Sensocure has developed and patented an innovative biomedical sensor (IscAlert™) designed for the earliest possible detection of ischemia, through measurement of the biomarker carbon dioxide (CO2).
We are now in the final stages of the commercialising of our curent IscAlert sensor that will address Hand and finger replantation, Ear, Nose and Throat (ENT) reconstructio, breast reconstruction and compartment syndrome in limbs.
The second half of the marked - internal organ implantation - will be addressed by the technology to be developed in the Eurostars Project IscAlert MICRO. Examples are Coronary Artery Bypass Graft (CABG), and liver and kidney transplantation. The innovations encompass the membrane, micro moulding, material handling and assembly of the miniaturised sensor.